北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 神经内科  > 期刊论文
学科主题: 临床医学
题名:
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures
作者: Wu, Xun-Yi1; Hong, Zhen; Wu, Xun2; Wu, Li-Wen3; Wang, Xue-Feng4; Zhou, Dong5; Zhao, Zhong-Xin6; Lv, Chuan-Zhen
关键词: Levetiracetam ; Epilepsy ; Add-on therapy ; Partial-onset seizures ; Refractory seizures ; Chinese patients
刊名: EPILEPSIA
发表日期: 2009-03-01
DOI: 10.1111/j.1528-1167.2008.01729.x
卷: 50, 期:3, 页:398-405
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Clinical Neurology
研究领域[WOS]: Neurosciences & Neurology
关键词[WOS]: IDIOPATHIC GENERALIZED EPILEPSY ; PHARMACOKINETICS ; EFFICACY ; BINDING ; PROTEIN ; SV2A ; DRUG
英文摘要:

Purpose: To evaluate efficacy and tolerability of levetiracetam (LEV; Keppra (R)) as add-on therapy in Chinese patients with refractory partial-onset seizures.

Methods: In this multicenter, double-blind, randomized, placebo-controlled trial, 206 patients aged 16-70 years with uncontrolled partial-onset seizures were randomized to receive LEV (n = 103) or placebo (n 103); 202 patients (LEV, n 102; placebo, n 100) comprised the intent-to-treat population. An 8-week historical baseline period confirmed eligibility according to seizure count. The 16-week treatment period consisted of a 4-week up-titration period (LEV, 1,000-3,000 mg/day in two equal divided doses) followed by a 12-week maintenance period. Efficacy assessments were based on weekly frequency of partial-onset seizures during the 16-week treatment period.

Results: LEV significantly decreased weekly partial-onset seizure frequency over placebo by 26.8% (p < 0.001). Median percentage reductions in weekly partial-onset seizure frequency from historical baseline were 55.9% for LEV and 13.7% for placebo (p < 0.001). The 50% responder rates were 55.9% for LEV, compared with 26.0% for placebo (p < 0.001). Freedom from partial-onset seizures during treatment period was achieved by 11 LEV patients (10.8%) and 2 placebo patients (2.0%) (p = 0.012). Adverse events were reported by 65 LEV-treated patients (63.1%) and 62 placebo-treated patients (60.2%); most were of mild-to-moderate intensity. The most common adverse events were somnolence (LEV, 17.5%; placebo, 17.5%), decreased platelet count (LEV, 9.7%; placebo, 9.7%), and dizziness (LEV, 7.8%; placebo, 13.6%).

Discussion: Add-on LEV was effective and well-tolerated in Chinese patients with refractory partial-onset seizures.

语种: 英语
项目资助者: UCB Pharma SA
WOS记录号: WOS:000266198000013
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65353
Appears in Collections:北京大学第一临床医学院_神经内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Fudan Univ, Inst Neurol, Huashan Hosp, Shanghai Med Coll, Shanghai 200433, Peoples R China
2.Peking Univ, Hosp 1, Dept Neurol, Beijing, Peoples R China
3.Peking Xiehe Hosp, Peking Union Med Coll, Dept Neurol, Beijing, Peoples R China
4.Chongqing Univ Med Sci, Affiliated Hosp, Dept Neurol, Chongqing, Peoples R China
5.Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China
6.Second Mil Med Univ, Dept Neurol, Shanghai Changzheng Hosp, Shanghai, Peoples R China

Recommended Citation:
Wu, Xun-Yi,Hong, Zhen,Wu, Xun,et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures[J]. EPILEPSIA,2009,50(3):398-405.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wu, Xun-Yi]'s Articles
[Hong, Zhen]'s Articles
[Wu, Xun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wu, Xun-Yi]‘s Articles
[Hong, Zhen]‘s Articles
[Wu, Xun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace